This week, the NHS approved two cannabis-derived medicines for the first time. It is a positive step for the future of legal cannabis in England.Read More
Researchers in the United Kingdom will be studying the effects of medical cannabis on children with brain tumors in a first of its kind study.Read More
Sativex®, available as a prescription only medicine, was developed by GW in specific response to calls from people with MS for a prescription cannabis-based medicine. Today’s launch means that MS patients suffering the spasms and cramping associated with spasticity have access to a new treatment option which has been shown to improve their symptoms where current treatments have failed.
Sativex® is manufactured by GW under Home Office licence at an undisclosed location in the UK. The medicine is being marketed in the UK by GW’s UK licensee, Bayer Schering Pharma.Read More